Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection
- PMID:25898944
- DOI: 10.1111/apt.13214
Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection
Abstract
Background: Unsatisfactory Helicobacter pylori eradication rates and therapy-associated side effects remain a problem.
Aim: To update our 2010 meta-analysis on the effects of Saccharomyces boulardii as supplementation to a standard eradication regimen on H. pylori eradication rates and therapy-associated side effects.
Methods: The Cochrane Library, MEDLINE and EMBASE databases were searched from July 2010 (end date of last search) to February 2015, with no language restrictions, for randomised controlled trials (RCTs); additional references were obtained from reviewed articles. Quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidelines.
Results: Eleven RCTs (2200 participants, among them 330 children) met the inclusion criteria. Of the 853 patients in the S. boulardii group, 679 (80%, 95% CI 77-82) experienced eradication compared with 608 of the 855 patients (71%, 95% CI 68-74) in the control group [relative risk (RR) 1.11, 95% confidence interval (CI) 1.06-1.17; moderate quality evidence]. S. boulardii compared with control reduced the risk of overall H. pylori therapy-related adverse effects (RR 0.44, 95% CI 0.31-0.64; moderate quality evidence), particularly of diarrhoea (RR 0.51, 95% CI 0.42-0.62; high quality evidence) and nausea [RR 0.6, 95% CI 0.44-0.83 (moderate quality of evidence)].
Conclusions: In the populations studied, the effectiveness of standard triple therapy was unsatisfactory. The addition of S. boulardii significantly increased the eradication rate, but it was still below the desired level of success. Saccharomyces boulardii significantly decreased some therapy-related side effects.
© 2015 John Wiley & Sons Ltd.
Similar articles
- Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis.Zhou BG, Chen LX, Li B, Wan LY, Ai YW.Zhou BG, et al.Helicobacter. 2019 Oct;24(5):e12651. doi: 10.1111/hel.12651. Epub 2019 Aug 14.Helicobacter. 2019.PMID:31414551
- The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.Liu LH, Han B, Tao J, Zhang K, Wang XK, Wang WY.Liu LH, et al.BMC Infect Dis. 2023 Dec 15;23(1):878. doi: 10.1186/s12879-023-08896-4.BMC Infect Dis. 2023.PMID:38102568Free PMC article.
- Optimum duration of regimens for Helicobacter pylori eradication.Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P.Yuan Y, et al.Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2.Cochrane Database Syst Rev. 2013.PMID:24338763Free PMC article.Review.
- Meta-analysis: sequential therapy for Helicobacter pylori eradication in children.Horvath A, Dziechciarz P, Szajewska H.Horvath A, et al.Aliment Pharmacol Ther. 2012 Sep;36(6):534-41. doi: 10.1111/j.1365-2036.2012.05229.x. Epub 2012 Jul 25.Aliment Pharmacol Ther. 2012.PMID:22827718Review.
- A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y.Hurduc V, et al.Acta Paediatr. 2009 Jan;98(1):127-31. doi: 10.1111/j.1651-2227.2008.00977.x. Epub 2008 Aug 4.Acta Paediatr. 2009.PMID:18681892Clinical Trial.
Cited by
- The Importance of Accurate Early Diagnosis and Eradication inHelicobacter pylori Infection: Pictorial Summary Review in Children and Adults.Marginean CM, Cioboata R, Olteanu M, Vasile CM, Popescu M, Popescu AIS, Bondari S, Pirscoveanu D, Marginean IC, Iacob GA, Popescu MD, Stanciu M, Mitrut P.Marginean CM, et al.Antibiotics (Basel). 2022 Dec 29;12(1):60. doi: 10.3390/antibiotics12010060.Antibiotics (Basel). 2022.PMID:36671261Free PMC article.Review.
- Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.McFarland LV, Evans CT, Goldstein EJC.McFarland LV, et al.Front Med (Lausanne). 2018 May 7;5:124. doi: 10.3389/fmed.2018.00124. eCollection 2018.Front Med (Lausanne). 2018.PMID:29868585Free PMC article.
- Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK.Roszczenko-Jasińska P, et al.Appl Microbiol Biotechnol. 2020 Dec;104(23):9891-9905. doi: 10.1007/s00253-020-10945-w. Epub 2020 Oct 14.Appl Microbiol Biotechnol. 2020.PMID:33052519Free PMC article.Review.
- Probiotic monotherapy andHelicobacter pylori eradication: A systematic review with pooled-data analysis.Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A.Losurdo G, et al.World J Gastroenterol. 2018 Jan 7;24(1):139-149. doi: 10.3748/wjg.v24.i1.139.World J Gastroenterol. 2018.PMID:29358890Free PMC article.Review.
- Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple forHelicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study.Qu P, Liu X, Xia X, Xie X, Luo J, Cheng S, Chi J, Liu P, Li H, Zhao W, Yang H, Xu C.Qu P, et al.Front Cell Infect Microbiol. 2022 Jul 8;12:903002. doi: 10.3389/fcimb.2022.903002. eCollection 2022.Front Cell Infect Microbiol. 2022.PMID:35880079Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous